Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus LANTRISUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus LANTRISUL.
FORBAXIN vs LANTRISUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Lantrisul (sulfadimethoxine) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking folic acid synthesis and ultimately nucleic acid production in susceptible bacteria.
IV: 500 mg every 12 hours, infused over 30 minutes.
Intravenous: 3 mg/kg every 8 hours for 14 days, then 5 mg/kg every 12 hours for 14 days; oral: 800 mg (10 mg/kg) twice daily after intravenous phase.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is 18 hours (range 16-20 h). This supports once-daily dosing; steady-state achieved after 3-4 days.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Approximately 70% renal excretion as unchanged drug, 15% fecal elimination via biliary secretion, 10% metabolized to inactive glucuronide conjugate eliminated renally, 5% other minor pathways.
Category C
Category C
Antibiotic
Antibiotic